Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.67.

NMRA has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research note on Friday, November 22nd.

Insider Transactions at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of the company's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares of the company's stock, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the sale, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The trade was a 8.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,400 shares of company stock valued at $686,361 in the last three months. 26.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Neumora Therapeutics

Several large investors have recently added to or reduced their stakes in NMRA. Amalgamated Bank lifted its position in shares of Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after purchasing an additional 2,402 shares in the last quarter. Quarry LP acquired a new position in shares of Neumora Therapeutics during the second quarter worth approximately $98,000. SkyOak Wealth LLC acquired a new position in shares of Neumora Therapeutics during the second quarter worth approximately $147,000. Principal Financial Group Inc. acquired a new position in shares of Neumora Therapeutics during the second quarter worth approximately $166,000. Finally, Intech Investment Management LLC acquired a new position in shares of Neumora Therapeutics during the third quarter worth approximately $175,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Price Performance

Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00. The stock has a 50 day simple moving average of $12.37 and a 200-day simple moving average of $11.49. The company has a market cap of $1.58 billion, a P/E ratio of -5.50 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the firm earned ($1.14) earnings per share. On average, equities research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.